Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine and ticagrelor for secondary prevention after atherosclerotic ischemic stroke
2022-001838-11Phase 3Active
- Sponsor
- Direction de la Recherche Clinique et de l'Innovation
- Start
- Jul 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ticagrelor, colchicine and aspirin in ischemic stroke and atherosclerotic cerebrovascular disease (3 arms), sponsored by Direction de la Recherche Clinique et de l'Innovation. Primary endpoint: Composite recurrent major vascular events. Started Jul 2022; status: active.
02
Drugs
ticagrelorcolchicineaspirin
03
Conditions
ischemic strokeatherosclerotic cerebrovascular disease
Beyond the preview
Go deeper on 2022-001838-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001838-11.